Initial results from EMPRISE show empagliflozin associated with fewer hospitalizations

EMPRISE is an 35,000-cohort study looking at treatment of diabetes with empagliflozin or DPP-4 inhibitors in the USA.

Go to the profile of Freya Leask
Apr 10, 2019
0
0

Boehringer Ingelheim (Germany) and Eli Lilly and Company (IN, USA) presented initial results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world evidence study at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2019 (25–28 March, CA, USA).

The results, from the first 2 years of the study, which is only evaluating US data, show that patients treated with empagliflozin were discharged earlier compared with those treated with DPP-4 inhibitors. Empagliflozin is also associated with a 22% relative risk reduction in all-cause hospitalizations and fewer recurrent emergency department visits.

“People with diabetes are more likely to be admitted to hospital from any cause than those without the condition, experiencing longer and more costly hospital stays. This can have a substantial impact on healthcare resources,” said Dr Mehdi Najafzadeh, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Instructor in Medicine, Harvard Medical School (both MA, USA) and study co-investigator.

“Initial results from the EMPRISE real-world study show that empagliflozin is associated with a relative risk reduction in hospitalizations and with a shorter length of hospital stay for people with type 2 diabetes.”

Source: https://www.boehringer-ingelheim.com/EMPRISE-real-world-study-results

Go to the profile of Freya Leask

Freya Leask

Publisher, Future Science Group

I am the Publisher of RegMedNet, 3DMedNet, RxNet and The Evidence Base, here to help users make the most of the websites and build our expert communities. I am passionate about digital and STM publishing, social media and story-telling. Please get in touch if you have any queries or comments!
13 Contributions
2 Followers
2 Following

No comments yet.